The honest answer is: it depends on who you are. For patients with moderate knee osteoarthritis or partial soft tissue injuries, there is genuine evidence of benefit. For others, the evidence is weak and the risk of spending thousands on a procedure that does little more than a corticosteroid injection is real.
This page presents both sides — including findings that most clinic websites do not disclose — so you can judge for your own situation.
Evidence in favor
These findings come primarily from clinic outcome studies — not randomized controlled trials.
70–80% patient-reported improvement in knee OA
Multiple clinic outcome registriesThese are uncontrolled studies from treating clinics. Patient-reported outcomes are subject to placebo effect.
Significant pain reduction at 6 months in moderate OA (KL 2–3)
Multiple prospective studiesBest results consistently seen before bone-on-bone stage. Grade matters more than any other variable.
Low adverse event rate across orthopedic indications
Systematic reviewsSerious adverse events are rare when procedures use the patient's own cells (autologous). Amniotic/umbilical cord products carry more variability.
Some patients delay or avoid knee replacement
Clinic outcome dataNot proven in randomized trials, but a consistent finding in long-term clinic follow-up for moderate OA.
Evidence against — or that complicates the picture
These findings are from independent randomized trials and regulatory bodies. They are rarely disclosed on clinic websites.
No significant advantage over corticosteroid injection at 12 months
MILES Trial — Nature Medicine, 2023 (n=480)The largest randomized controlled trial to date. Clinics rarely disclose this. Both groups improved — but stem cells did not improve more.
FDA classifies most orthopedic stem cell products as 'investigational'
FDA regulatory positionThis means there is no FDA-approved stem cell product for orthopedic use. Providers operate under enforcement discretion.
ACR and Arthritis Foundation do not recommend it for OA
ACR 2022 GuidelinesMajor rheumatology organizations don't include stem cell therapy in their treatment recommendations due to insufficient evidence.
Product inconsistency: 'stem cell' is a marketing term
Multiple independent analysesMany products marketed as 'stem cell therapy' contain few or no viable stem cells. Amniotic and cord blood products are often processed in ways that eliminate cell viability.
Who is — and isn't — a good candidate
Kellgren-Lawrence Grade 2–3 knee OA
Moderate osteoarthritis with joint space narrowing but not bone-on-bone. This is where the strongest response data exists.
Partial meniscus tears, degenerative tears
Especially in patients who want to avoid or delay arthroscopic surgery.
Partial ligament tears (ACL, MCL)
Chronic instability or partial tears in athletes who want to avoid reconstruction.
Failed conservative treatment
PT, NSAIDs, and corticosteroid injections tried and insufficient. Stem cell therapy as a bridge before surgery is a reasonable option.
High-function patients who need to avoid surgery downtime
Athletes, active professionals who can't take 6–12 months off for a replacement recovery.
Bone-on-bone OA (KL Grade 4)
Most providers won't treat it, and outcome data is weak. At this stage, total knee replacement has a stronger evidence base.
Complete ACL rupture with functional instability
Full ruptures generally require surgical reconstruction. Stem cell therapy is not a substitute.
Anyone promised a 'cure'
No provider can guarantee outcomes. If a clinic's pitch sounds too certain, that is a red flag.
Patients unwilling or unable to complete rehab
The biology requires the joint to be actively loaded during healing. Outcome data assumes post-procedure physical therapy.
What you're paying for
All orthopedic stem cell procedures are cash-pay. Medicare and private insurance do not cover them. Prices vary by product type, imaging guidance, and provider.
BMAC (bone marrow aspirate concentrate)
$4,000–$8,500PRP (platelet-rich plasma)
$1,500–$4,000Adipose-derived (fat tissue)
$5,000–$10,000Amniotic / umbilical cord products
$3,500–$8,000Combined protocol (BMAC + PRP)
$7,000–$12,500Always ask for an itemized breakdown before committing. Some providers quote low but charge separately for imaging guidance, follow-up injections, or processing fees. Full cost guide →
The variable nobody mentions: provider quality
The evidence debate about stem cell therapy largely misses the most important variable: how the procedure is performed. Image-guided injection (ultrasound or fluoroscopy) dramatically improves the precision of cell placement. Unguided injections — which some lower-cost providers use — have significantly weaker outcomes.
The type of product also matters. Autologous bone marrow concentrate (using your own cells) has the strongest evidence base. Many products marketed as "stem cell therapy" — particularly amniotic and umbilical cord products — contain few or no viable stem cells after processing.
In other words: the same underlying biology can produce very different outcomes depending on who performs it and how. The right question isn't just "does stem cell therapy work?" — it's "does this provider do it correctly?"
Before you commit, ask these 5 questions
1.What is my Kellgren-Lawrence grade, and what does your outcomes data show for patients at that grade?
2.What product do you use — autologous bone marrow, adipose-derived, or a processed cord/amniotic product?
3.Is the injection image-guided? (Ultrasound or fluoroscopy.)
4.Do you have your own outcomes registry? Can I see aggregated results for cases like mine?
5.What happens if I don't improve — is there a follow-up protocol?
Find a verified provider
Every provider in the RegenSelect directory has been verified to offer legitimate regenerative medicine with an orthopedic focus. No paid placements. No unverified listings.